Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach
Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences ("NYAS") symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026, in New York, NY.
The symposium brings together leading experts from academia, industry and clinical research to explore advances in fibrosis biology, emerging multiomic insights and the development of novel therapeutic approaches across a range of fibrotic diseases.
Dr. Jones' presentation, titled "Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn's Disease (FSCD)," will discuss the significant unmet need associated with FSCD, the biological mechanisms underlying intestinal fibrosis and the potential role of locally bioactivated PDE4 inhibition as a novel therapeutic approach.